- Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
-
Tay WL, Tay D
- KMID: 2529210
- Endocrinol Metab.
- 2022 Apr;37(2):183-194.
- doi: 10.3803/EnM.2021.1369
Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL),... -
- CITED
-
- Close
- SHARE
-
- Close
